Skip to main content

AACR 2019

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Conference coverage from the AACR Annual Meeting 2019

All the breaking news and expert interviews from the meeting in Atlanta (March 29–April 3, 2019).

TATTON trial outcomes

03-04-2019 | Non-small cell lung cancer | AACR 2019 | News

Osimertinib combinations promising for NSCLC patients with acquired resistance to EGFR–TKIs

Data from the phase Ib TATTON trial suggest that patients with EGFR-mutated non-small-cell lung cancer who have progressed on prior EGFR–tyrosine kinase inhibitor therapy could benefit from adding either the MET inhibitor savolitinib or the MEK inhibitor selumetinib to osimertinib.

01-04-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: TATTON trial of savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC

Advisory board member and study author Lecia Sequist takes us through the findings of the savolitinib plus osimertinib cohort of the phase Ib TATTON trial of advanced non-small-cell cancer patients who have developed resistance to EGFR inhibitor therapy (4:48).

01-04-2019 | Non-small cell lung cancer | Video | Article

Expert commentary: TATTON trial – Exploring options for EGFR inhibitor-resistant NSCLC

Roy Herbst provides his views on the phase Ib TATTON study that combined osimertinib with either the MET inhibitor savolitinib or the MEK inhibitor selumetinib in the advanced, resistant NSCLC setting (2:53).

Research news

11-04-2019 | Prostate cancer | AACR 2019 | News

Prostate cancer incidence, mortality has decreased or stabilized in many countries

Research reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, shows that the incidence of prostate cancer and associated mortality has generally declined or remained steady in most of the countries with available data.

10-04-2019 | Non-small cell lung cancer | AACR 2019 | News

Clinical value of genotyping cfDNA demonstrated in advanced NSCLC setting

The NILE study has shown the noninferiority of cell-free DNA analysis, so-called liquid biopsy, to the standard of care for identifying targetable biomarkers in individuals with treatment-naïve metastatic non-small-cell lung cancer.

08-04-2019 | Castration-resistant prostate cancer | AACR 2019 | News

SPARTAN: Apalutamide benefit seen for luminal, basal nonmetastatic CRPC

Supplementing androgen deprivation therapy with apalutamide improves metastasis-free survival in patients with the luminal and basal subtypes of nonmetastatic castration-resistant prostate cancer, indicates an analysis of the randomized SPARTAN trial.

Expert interviews

02-04-2019 | Immunotherapy | Video | Article

Researcher comment: The impact of lifestyle factors on the gut microbiome and immunotherapy response

Christine Spencer outlines her study investigating the effect of diet and supplements on gut microbiota and response to anti-PD-1 therapy in patients with metastatic melanoma, and discusses how the findings may be relevant to other tumor types (3:43).

02-04-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: Liquid biopsy noninferior to tissue biopsy for identifying genomic targets in metastatic NSCLC

Researcher Vassiliki Papadimitrakopoulou describes the findings of the prospective NILE study evaluating the clinical utility of genotyping cell-free DNA in patients with a new diagnosis of metastatic non-small-cell lung cancer (3:21).

01-04-2019 | Malignant pleural disease | Video | Article

Researcher comment: CAR T-cell therapy for malignant pleural disease

Prasad Adusumilli outlines the key results of their phase I trial showing promising safety and efficacy of a mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease, and also discusses the next steps (4:09).

Image Credits